Identification and Structure–Activity Relationship Studies of Small‐Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1 |
| |
Authors: | Dr. Dina Robaa Dr. Tobias Wagner Chiara Luise Dr. Luca Carlino Joel McMillan Dr. Ralf Flaig Prof. Dr. Roland Schüle Prof. Dr. Manfred Jung Prof. Dr. Wolfgang Sippl |
| |
Affiliation: | 1. Institute of Pharmacy, Martin Luther University of Halle-Wittenberg, Halle/Saale, Germany;2. Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany;3. Department of Urology and Center for Clinical Research, University of Freiburg Medical Center, Freiburg, Germany;4. Diamond Light Source Ltd., Didcot, Oxfordshire, UK;5. German Cancer Research Center (DKFZ), Heidelberg, Germany;6. German Cancer Consortium (DKTK), Freiburg, Germany |
| |
Abstract: | The methyllysine reader protein Spindlin1 has been implicated in the tumorigenesis of several types of cancer and may be an attractive novel therapeutic target. Small‐molecule inhibitors of Spindlin1 should be valuable as chemical probes as well as potential new therapeutics. We applied an iterative virtual screening campaign, encompassing structure‐ and ligand‐based approaches, to identify potential Spindlin1 inhibitors from databases of commercially available compounds. Our in silico studies coupled with in vitro testing were successful in identifying novel Spindlin1 inhibitors. Several 4‐aminoquinazoline and quinazolinethione derivatives were among the active hit compounds, which indicated that these scaffolds represent promising lead structures for the development of Spindlin1 inhibitors. Subsequent lead optimization studies were hence carried out, and numerous derivatives of both lead scaffolds were synthesized. This resulted in the discovery of novel inhibitors of Spindlin1 and helped explore the structure–activity relationships of these inhibitor series. |
| |
Keywords: | AlphaLISA assay lead optimization methyllysine readers Spindlin1 virtual screening |
|
|